These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 36551586)

  • 41. Side effects of CDK4/6 inhibitors in the treatment of HR+/HER2- advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials.
    Yang L; Xue J; Yang Z; Wang M; Yang P; Dong Y; He X; Bao G; Peng S
    Ann Palliat Med; 2021 May; 10(5):5590-5599. PubMed ID: 34107710
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and feasibility of CDK4/6 inhibitors treatment combined with radiotherapy in patients with HR-positive/HER2-negative breast cancer. A systematic review and meta-analysis.
    Kubeczko M; Jarząb M; Gabryś D; Krzywon A; Cortez AJ; Xu AJ
    Radiother Oncol; 2023 Oct; 187():109839. PubMed ID: 37536378
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer: a systematic review.
    Zhu L; Wang M; Luo X; Li H; Shan H; Du Q; Zhai Q
    Ann Transl Med; 2022 Feb; 10(4):233. PubMed ID: 35280368
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of abemaciclib-based therapy versus tucidinostat-based therapy after progression on palbociclib in patients with HR
    Yuan Y; Zhang S; Wang T; Wang B; Wang S; Shi J; Sun T; Yin Y; Ouyang Q; Li J; Wen Y; Zhang L; Jiang Z
    Transl Breast Cancer Res; 2023; 4():10. PubMed ID: 38751483
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials.
    Messina C; Cattrini C; Buzzatti G; Cerbone L; Zanardi E; Messina M; Boccardo F
    Breast Cancer Res Treat; 2018 Nov; 172(1):9-21. PubMed ID: 30054831
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A multicenter analysis of treatment patterns and clinical outcomes of subsequent therapies after progression on palbociclib in HR+/HER2- metastatic breast cancer.
    Li Y; Li W; Gong C; Zheng Y; Ouyang Q; Xie N; Qu Q; Ge R; Wang B
    Ther Adv Med Oncol; 2021; 13():17588359211022890. PubMed ID: 34178122
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis.
    Guo Q; Lin X; Ye L; Xu R; Dai Y; Zhang Y; Chen Q
    Target Oncol; 2019 Apr; 14(2):139-148. PubMed ID: 30941621
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis.
    Ji D; Luo Y; Wang J; Chen S; Lan B; Ma F; Xu B; Fan Y
    BMC Cancer; 2023 Aug; 23(1):805. PubMed ID: 37644396
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort.
    Pla H; Felip E; Obadia V; Pernas S; Viñas G; Margelí M; Fort-Culillas R; Del Barco S; Sabaté N; Fort E; Lezcano C; Cirauqui B; Quiroga V; Stradella A; Gil Gil M; Esteve A; Recalde S
    Clin Transl Oncol; 2024 Jul; 26(7):1748-1758. PubMed ID: 38519708
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy.
    Rozenblit M; Mun S; Soulos P; Adelson K; Pusztai L; Mougalian S
    Breast Cancer Res; 2021 Jan; 23(1):14. PubMed ID: 33514405
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer.
    Zhou J; Wu X; Zhang H; Wang X; Yuan Y; Zhang S; Jiang Z; Wang T
    Breast; 2022 Dec; 66():255-261. PubMed ID: 36375386
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review.
    Nagaraj G; Ma CX
    Adv Ther; 2021 Jan; 38(1):109-136. PubMed ID: 33190190
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2- Advanced Breast Cancer.
    Fasching PA; Delea TE; Lu YS; De Boer R; Hurvitz SA; Moynahan A; Chandiwana D; Lanoue B; Hu H; Thuerigen A; O'Shaughnessy J
    Cancer Manag Res; 2021; 13():8179-8189. PubMed ID: 34754238
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of HER2-low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR-positive/HER2-negative metastatic breast cancer: A prospective study.
    Wu Y; Mo H; Xu H; Wang Y; Wang J; Ma F; Xu B
    Thorac Cancer; 2024 Apr; 15(12):965-973. PubMed ID: 38480513
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women.
    Gupta N; Gupta D; Dixit J; Mehra N; Singh A; Krishnamurthy MN; Jyani G; Rajsekhar K; Kalaiyarasi JP; Roy PS; Malik PS; Mathew A; Malhotra P; Gupta S; Kumar L; Kataki A; Prinja S
    Appl Health Econ Health Policy; 2022 Jul; 20(4):609-621. PubMed ID: 35534752
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Real-world experience with CDK4/6 inhibitors in hormone receptor-positive metastatic and recurrent breast cancer: findings from an Asian population.
    Chen BF; Tsai YF; Chao TC; Lien PJ; Lin YS; Feng CJ; Chen YJ; Cheng HF; Liu CY; Lai JI; Tseng LM; Huang CC
    Clin Exp Med; 2024 Aug; 24(1):185. PubMed ID: 39133334
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Exploring the Clinical Impact of RANK Pathway Inhibition in Advanced Breast Cancer: Insights From a Retrospective Study on CDK4/6 Inhibitors and Antiresorptive Therapy.
    Akdag G; Dogan A; Yildirim S; Kinikoglu O; Mokresh ME; Alomari O; Turkoglu E; Isik D; Sürmeli H; Basoglu T; Sever ON; Odabas H; Yildirim ME; Turan N
    Cureus; 2024 Jun; 16(6):e63362. PubMed ID: 39070363
    [TBL] [Abstract][Full Text] [Related]  

  • 58. APOBEC Mutational Signatures in Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancers Are Associated With Poor Outcomes on CDK4/6 Inhibitors and Endocrine Therapy.
    Sammons S; Raskina K; Danziger N; Alder L; Schrock AB; Venstrom JM; Knutson KL; Thompson EA; McGregor K; Sokol E; Chumsri S
    JCO Precis Oncol; 2022 Oct; 6():e2200149. PubMed ID: 36315915
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience.
    Wander SA; Han HS; Zangardi ML; Niemierko A; Mariotti V; Kim LSL; Xi J; Pandey A; Dunne S; Nasrazadani A; Kambadakone A; Stein C; Lloyd MR; Yuen M; Spring LM; Juric D; Kuter I; Sanidas I; Moy B; Mulvey T; Vidula N; Dyson NJ; Ellisen LW; Isakoff S; Wagle N; Brufsky A; Kalinsky K; Ma CX; O'Shaughnessy J; Bardia A
    J Natl Compr Canc Netw; 2021 Mar; ():1-8. PubMed ID: 33761455
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Real-World Treatment Patterns and Clinical Outcomes among Patients Receiving CDK4/6 Inhibitors for Metastatic Breast Cancer in a Canadian Setting Using AI-Extracted Data.
    Moulson R; Feugère G; Moreira-Lucas TS; Dequen F; Weiss J; Smith J; Brezden-Masley C
    Curr Oncol; 2024 Apr; 31(4):2172-2184. PubMed ID: 38668064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.